	US 11,780,911 B2
	Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
Matthew Germinaro, Philadelphia, PA (US); Christopher O'Brien, Lafayette Hill, PA (US); and Jacqueline Perrigoue, Oreland, PA (US)
Assigned to JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on May 21, 2020, as Appl. No. 16/880,118.
Claims priority of provisional application 62/851,968, filed on May 23, 2019.
Claims priority of provisional application 62/896,205, filed on Sep. 5, 2019.
Prior Publication US 2020/0369761 A1, Nov. 26, 2020
Int. Cl. C07K 16/24 (2006.01); A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61P 1/04 (2006.01); A61P 29/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/244 (2013.01) [A61K 9/0019 (2013.01); A61K 39/395 (2013.01); A61P 1/04 (2018.01); A61P 29/00 (2018.01); C07K 16/241 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)]

42 Claims

1. A method of treating an inflammatory bowel disease in a patient, the method comprising:

a) administering a first co-therapeutically effective amount of an IL-23 inhibitor; and

b) administering a second co-therapeutically effective amount of a TNF-α inhibitor,

wherein the method is effective to treat the inflammatory bowel disease and the patient shows a clinical response,

wherein the TNF-α inhibitor and the IL-23 inhibitor are administered in a ratio of from 1:2 to 2:1 (w/w) or from 15:1 to 400:1 (w/w).